Oncolytic adenovirus in combination with PD-L1-targeted radioimmunotherapy exerts synergistic antitumor effect against pancreatic cancer - PubMed
3 hours ago
- #Oncolytic Virus
- #Pancreatic Cancer
- #Radioimmunotherapy
- Combining an oncolytic adenovirus with PD-L1-targeted radioimmunotherapy shows a synergistic antitumor effect against pancreatic cancer.
- The oncolytic adenovirus (HY-oAd) co-expresses IL-12, GM-CSF, and relaxin, increasing PD-L1 expression and degrading the tumor's extracellular matrix.
- This enhances accumulation of anti-PD-L1 antibodies (aPD-L1) and radiolabeled versions (e.g., 177Lu-aPD-L1) in pancreatic tumors.
- Combination therapy (HY-oAd + aPD-L1 or 177Lu-aPD-L1) outperforms monotherapy in both subcutaneous and orthotopic tumor models.
- Improved antitumor effects are due to enhanced infiltration and activation of dendritic cells and T cells (CD4+ and CD8+).
- The approach addresses desmoplastic and immune-desert phenotypes that limit conventional treatments in pancreatic cancer.